Analysis Group Researchers to Present New Outcomes Research at the 2025 AMCP Conference

March 10, 2025

Analysis Group’s HEOR, Epidemiology & Market Access practice will present 13 posters, including bronze and silver awardees and three encore presentations, at the Academy of Managed Care Pharmacy’s (AMCP’s) 2025 meeting, which will be held from March 31 to April 3 in Houston, TX.

Silver Ribbon

  • “The Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) in the United States (US): Updated Results from a Cost of Care Sequencing Model for Patients with CLL,” coauthored by an Analysis Group team – including Managing Principal Annie Guérin, Manager Nisha Hazra, Manager Honghao Fang, and Senior Analyst Weiye Chen – in collaboration with researchers from Dana Farber Cancer Institute, Stanford Cancer Institute, Fred Hutchinson Cancer Research Center, and AbbVie/Genentech (sponsor). Wednesday, April 2, 11:30–1:00 p.m.

Bronze Ribbon

  • “Real-world utilization of gonadotropins and the associated cumulative live birth rates in the US: A retrospective claims database analysis,” coauthored by an Analysis Group team – including Managing Principal Min Yang, Vice President Weiguang Xue, Associate Anya Jiang, and Senior Analyst Angela Zhao – in collaboration with researchers from Northwestern University and Ferring Pharmaceuticals (sponsor). Wednesday, April 2, 1:00–2:30 p.m.
  • “Identifying Patient Characteristics Associated with Guideline Directed Medical Therapy Uptake and Healthcare Resource Use in Patients Newly Diagnosed with Heart Failure with Reduced Ejection Fraction in the United States,” coauthored by an Analysis Group team – including Vice President Yan Song, Manager Nicolae Done, and Associate Ian Nason – in collaboration with researchers from Nell Hodgson Woodruff School of Nursing, Emory University, Duke Clinical Research Institute, and Merck (sponsor). Wednesday, April 2, 1:00–2:30 p.m.

Additional poster presentations include:

  • “Cost-effectiveness analysis of SI-6603 for Lumbar Disc Herniation (LDH) in the United States (US),” coauthored by an Analysis Group team – including Managing Principal Min Yang, Manager Wei Song, Associate Boya Lin, Associate Dongni Ye, and Senior Analyst Sydney Ng – in collaboration with researchers from LSU School of Medicine and Ferring Pharmaceuticals (sponsor). Wednesday, April 2, 1:00–2:30 p.m.
  • “Real-World Patient Profile, Persistence, and Adherence Data on Early Hyrimoz® Utilization: A Retrospective Claims-Based Analysis,” coauthored by an Analysis Group team – including Managing Principal Annie Guérin, Vice President Patrick Gagnon, Associate Rebecca Bungay, Associate Jerome Bedard, and Research Professional Nathan Gobeil – in collaboration with researchers from Sandoz. Wednesday, April 2, 1:00–2:30 p.m.
  • “Revealing Long-Term Value: Cost-Effectiveness of Ribociclib (RIB) in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2−) Early Breast Cancer (EBC),” coauthored by an Analysis Group team – including Vice President Xinglei Chai, Vice President Jenny Zhou, and Associate Fan Yang – in collaboration with researchers from Dana Farber Cancer Institute, Icahn School of Medicine at Mount Sinai, Nucleus Global, University of Pittsburgh School of Medicine, University of Illinois Cancer Center, and Novartis (sponsor). Wednesday, April 2, 11:30–1:00 p.m.
  • “Adherence to once-weekly injectable semaglutide and associated risk factors in patients with type 2 diabetes in the United States,” coauthored by an Analysis Group team – including Vice President Yan Song, Vice President Yan Wang, and Associate Joana Boland – in collaboration with researchers from Brigham and Women’s Hospital and Novo Nordisk (sponsor). Wednesday, April 2, 11:30–1:00 p.m.
  • “Oral semaglutide adherence and associated risk factors in patients with type 2 diabetes in the United States,” coauthored by an Analysis Group team – including Vice President Yan Song, Vice President Yan Wang, and Associate Joana Boland – in collaboration with researchers from Brigham and Women’s Hospital and Novo Nordisk (sponsor). Wednesday, April 2, 11:30–1:00 p.m.
  • “Economic Evaluations of FcRn Inhibitors in Generalized Myasthenia Gravis,” coauthored by an Analysis Group team – including Managing Principal Hongbo Yang, Manager Mandy Du, and Senior Analyst Xin Chen – in collaboration with researchers from Health Plan of Nevada and Argenx (sponsor). Wednesday, April 2, 11:30–1:00 p.m.
  • “Real-world treatment patterns and economic burden among adult patients diagnosed with neurofibromatosis type 1 and plexiform neurofibromas (NF1-PN) in the United States,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President Marianne Cunnington, Manager Qing Liu, Senior Analyst Grace Chen, and HEOR Data Analyst Specialist Dominique Lejeune – in collaboration with researchers from Alexion, AstraZeneca Rare Disease, Harvard Medical School, the Department of Neurology and Cancer Center at Massachusetts General Hospital, and Merck (sponsor). Wednesday, April 2, 11:30–1:00 p.m.

Encore presentations:

  • “Overall survival in patients with metastatic castration sensitive prostate cancer treated with apalutamide versus abiraterone acetate – a head-to-head analysis of real-world patients in the United States,” coauthored by an Analysis Group team – including Vice President Dominic Pilon, Manager Carmine Rossi, Associate Frederic Kinkead, and Senior Research Professional Lilian Diaz – in collaboration with researchers from Carolina Urologic Research Center, Chesapeake Urology, Winship Cancer Institute of Emory University, and Johnson & Johnson (sponsor). Wednesday, April 2, 11:30–1:00 p.m.
  • “Real-world head-to-head analysis of overall survival in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide versus enzalutamide in the United States,” coauthored by an Analysis Group team – including Vice President Dominic Pilon, Manager Carmine Rossi, Associate Frederic Kinkead, and Senior Research Professional Lilian Diaz – in collaboration with researchers from Carolina Urologic Research Center, Chesapeake Urology, Winship Cancer Institute of Emory University, and Johnson & Johnson (sponsor). Wednesday, April 2, 11:30–1:00 p.m.
  • “Real-world treatment patterns and clinical conditions of patients with basal cell carcinoma who received sonidegib or vismodegib treatment,” coauthored by an Analysis Group team – including Managing Principal Mihran Yenikomshian, Vice President Lynn Huynh, Vice President Enrico Zanardo, and Manager Deepshekhar Gupta – in collaboration with researchers from Icahn School of Medicine at Mount Sinai, the Moffitt Cancer Center and Research Institute, Viver Health, and Sun Pharma (sponsor). Wednesday, April 2, 11:30–1:00 p.m.